Formestane
Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years.
Overview
Formestane was developed by Angela Brodie's laboratory in the 1970s as the first aromatase inhibitor designed to be selective, in contrast to aminoglutethimide, and Ciba-Geigy brought it to market in the United Kingdom and other European countries in 1993 for advanced postmenopausal breast cancer after tamoxifen. It lowered oestrogen levels effectively but had to be injected because of poor oral bioavailability. Anastrozole, letrozole and the oral steroidal inactivator exemestane followed between 1995 and 1999 and displaced it; it was withdrawn from most markets in the mid-2000s. It was never approved in the United States.
An androstenedione analogue that aromatase binds and converts to a reactive intermediate, permanently inactivating the enzyme that makes oestrogen. Connects to Aromatase (CYP19A1).
1.Formestane acts on Aromatase (CYP19A1), the hormone receptor or the enzyme that makes the hormone.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Formestane" OR ABSTRACT:"Formestane" OR TITLE:"Lentaron" OR ABSTRACT:"Lentaron" OR TITLE:"4-Hydroxyandrostenedione" OR ABSTRACT:"4-Hydroxyandrostenedione" OR TITLE:"4-OHA" OR ABSTRACT:"4-OHA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Formestane, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAminoglutethimide
Shares Aromatase (CYP19A1), Exemestane, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentFluoxymesterone
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentDiethylstilbestrol
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentTechnetium Tc-99m sulfur colloid
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentHistrelin
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentAbarelix
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentBuserelin
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentDoxifluridine
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.